Related Experiment Videos
Hypokalaemic periodic paralysis unresponsive to acetazolamide
Clinical and Experimental Neurology
|January 1, 1981
Summary
This study presents a case of hypokalemic periodic paralysis unresponsive to acetazolamide. Triamterene effectively managed symptoms and maintained normal potassium levels without supplementation.
Area of Science:
- Neurology
- Endocrinology
- Genetics
Background:
- Hypokalemic periodic paralysis (HPP) is a rare genetic disorder characterized by episodes of muscle weakness.
- While acetazolamide is a common treatment, some HPP subtypes are unresponsive or even exacerbated by it.
Observation:
- A 14-year-old farm laborer presented with classical HPP symptoms.
- The patient's condition did not respond to acetazolamide, which paradoxically triggered attacks.
- Potassium salts provided prompt but temporary symptom relief.
Findings:
- The administration of triamterene (100mg daily) led to a complete cessation of HPP attacks for 12 months.
- Serum potassium levels remained normal throughout the treatment period.
- No supplementary potassium was required with triamterene therapy.
Implications:
- Triamterene represents a potential therapeutic option for acetazolamide-unresponsive HPP.
- This finding expands treatment strategies for managing periodic paralysis.
- Further research into triamterene's efficacy in diverse HPP populations is warranted.